Citizens initiated coverage of Opus Genetics with an Outperform rating and $12 price target. The company is developing a portfolio of AAV-based gene therapies for inherited retinal diseases, with the goal of preserving and/or restoring vision in patients who lack any treatments today, the analyst tells investors in a research note. The firm says Opus' inherited retinal disease focus provides multiple benefits for a large commercial opportunity.
